A successful SARS-CoV-2 vaccine must be not only safe and protective but must also meet the demand on a global scale at low cost. Using the current influenza virus vaccine production capacity to manufacture an egg-based inactivated Newcastle disease virus (NDV)/SARS-CoV-2 vaccine would meet that challenge. Here, we report pre-clinical evaluations of an inactivated NDV chimera stably expressing the membrane-anchored form of the spike (NDV-S) as a potent COVID-19 vaccine in mice and hamsters. The inactivated NDV-S vaccine was immunogenic, inducing strong binding and/or neutralizing antibodies in both animal models. More importantly, the inactivated NDV-S vaccine protected animals from SARS-CoV-2 infections or significantly attenuated SARS-CoV-2 induced disease. In the presence of an adjuvant, antigen-sparing could be achieved, which would further reduce the cost while maintaining the protective efficacy of the vaccine.

中文翻译：

---

一种新城疫病毒（NDV），其表达膜锚定的尖峰是一种经济高效的灭活SARS-CoV-2疫苗。

成功的SARS-CoV-2疫苗不仅必须是安全和防护性的，而且还必须以低成本满足全球规模的需求。利用当前的流感病毒疫苗生产能力来生产基于鸡蛋的灭活新城疫病毒（NDV）/ SARS-CoV-2疫苗将迎接这一挑战。在这里，我们报告了灭活的NDV嵌合体的临床前评价，该嵌合体稳定表达强力的膜锚定形式的尖峰（NDV-S）作为强效的COVID-19疫苗在小鼠和仓鼠中。灭活的NDV-S疫苗具有免疫原性，可在​​两种动物模型中诱导强结合和/或中和抗体。更重要的是，灭活的NDV-S疫苗可保护动物免受SARS-CoV-2感染或SARS-CoV-2诱导的疾病明显减轻。在佐剂的存在下，可以节省抗原，